Selected Publications from 2020

Publications

Breast cancer surgery during the COVID-19 pandemic
Highton LR, Dave RV, Barnes NLP.
BJS Society  2020  107/10  e380-e380
 
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ.
Lancet Oncol.   2020  2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. 
 
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, Chilamakuri CSR, Glont SE, Archer Goode E, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll JS.
Nat Genet. 2020 Feb;52(2):187-197. doi: 10.1038/s41588-019-0541-5. Epub 2020 Jan 6. Erratum in: Nat Genet. 2020 Jan 31;: PMID: 31913353.  2010   
 
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
Simões BM, Santiago-Gómez A, Chiodo C, Moreira T, Conole D, Lovell S, Alferez D, Eyre R, Spence K, Sarmiento-Castro A, Kohler B, Morisset L, Lanzino M, Andò S, Marangoni E, Sims AH, Tate EW, Howell SJ, Clarke RB
Oncogene. 2020 May 30. doi: 10.1038/s41388-020-1335-z.  2020   
 
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M, Skene A, Vidya R, Cheang M, Banerji J, Morden J, Sidhu K, Dodson A, Bliss JM, Dowsett M.
Lancet Oncol. 2020 Nov;21(11):1443-1454. doi: 10.1016/S1470-2045(20)30458-7.  2020   
 


Seminars

Date:  22 January 2025, 14:00
Speaker:  Mark Clemons & John Hilton
From:  Canada
Title:  TBC
Host:  Sacha Howell
 
Date:  12 February 2025, 00:00
Speaker:  Andrew Tutt
From:  The Institute of Cancer Research (ICR), London
Title:  TBC
Host:  Rob Clarke